Trial Profile
A Double-Blind, Placebo-Controlled, Phase 2, Responsive Adaptive Randomization Study of ORP-101 in Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs ORP 101 (Primary)
- Indications Irritable bowel syndrome
- Focus Proof of concept; Therapeutic Use
- Acronyms PREVAIL
- Sponsors OrphoMed
- 10 Jan 2022 Planned End Date changed from 1 Dec 2021 to 4 Oct 2022.
- 04 Jan 2022 According to an OrphoMed media release, the phase 2 clinical trial has been successfully completed in November 2021.
- 04 Jan 2022 Status changed from active, no longer recruiting to completed, according to an OrphoMed media release.